curacel® fibrillar combination dressing
city medical store - sole proprietorship l.l.c netherlands - cf-738 10 pieces box 102 x 102 mm - dressing - combination - n/a
curacel® high density device dressing
city medical store - sole proprietorship l.l.c netherlands - 10’s [10 patches of 15.2 x 23 cm] ch-660 - dressing - device - n/a
tenatac® haemostatic absorbable gelatine sponge device
city medical store - sole proprietorship l.l.c netherlands - 5’s [80x50x10mm] tt-08050 - sponge - device - medical devices-medical devices
windexco syrup
winwa medical sdn. bhd. - chlorpheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride -
cpg 312 gel breast implant cohesive iii, low height, moderate plus profile
estradiol valerate injection, solution
perrigo company - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 20 mg in 1 ml - estradiol valerate injection is indicated in the: 1. treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of cancer of the breast. 3. known or suspected estrogen-dependent neoplasia. 4. active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5. active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial i
estradiol valerate injection, solution
american regent, inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate injection is indicated in the: 1. treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of cancer of the breast. 3. known or suspected estrogen-dependent neoplasia. 4. active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5. active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial i
box jellyfish antivenom
box jellyfish antivenom -
curacel fibrillar absorbable haemostat - surgical plant polysaccharide haemostatic agent
integrity hospital supplies pty ltd -
curacel hd (high density) absorbable haemostat - surgical plant polysaccharide haemostatic agent
integrity hospital supplies pty ltd -